June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Smoking as a risk factor for proliferative vitreoretinopathy
Author Affiliations & Notes
  • Damla Oncel
    Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, United States
  • Samuel Minaker
    Rush University Medical Center, Chicago, Illinois, United States
  • Emily Shepherd
    Rush University Medical Center, Chicago, Illinois, United States
  • Sam Rezaei
    Rush University Medical Center, Chicago, Illinois, United States
  • Nick Boucher
    BHSH Spectrum Health, Grand Rapids, Michigan, United States
  • Nitika Aggarwal
    BHSH Spectrum Health, Grand Rapids, Michigan, United States
  • Mathew MacCumber
    Rush University Medical Center, Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Damla Oncel None; Samuel Minaker None; Emily Shepherd None; Sam Rezaei None; Nick Boucher None; Nitika Aggarwal None; Mathew MacCumber None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4556. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Damla Oncel, Samuel Minaker, Emily Shepherd, Sam Rezaei, Nick Boucher, Nitika Aggarwal, Mathew MacCumber; Smoking as a risk factor for proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4556.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Proliferative vitreoretinopathy (PVR) is a serious complication that can occur following rhegmatogenous retinal detachment (RRD). Smoking has previously been linked to the development of PVR after RRD due to trauma. In this study, we aimed to explore smoking as a risk factor for PVR due to RRD regardless of trauma history in a large patient database.

Methods : Using the relevant ICD codes, patients of any demographic who have a diagnosis of RRD and PVR, and who have been seen in the last seven years (January 2015-November 2022) were identified in the Vestrum Health database. In addition, patients who had a post-op visit within one month following RRD diagnosis date were selected. The eyes that had proliferative diabetic retinopathy and those that had PVR prior to RRD diagnosis date were excluded. The rate of PVR was calculated in each subset patient population that were grouped according to their smoking status. In addition, demographic information such as age, gender, and clinical information including lens status and visual acuity was collected.

Results : There were 48,345 eyes that had a post-op visit within 1 month following RRD diagnosis of which 62% were male. Out of these eyes, 16% had RRD in both eyes. The rate of PVR was highest in the eyes that had visual acuity less than 20/200. After the RRD, 9% of the eyes developed PVR and of those that developed PVR, 78.2% had gone through vitrectomy. The rate of PVR was highest in active smoker subset population (10.1%), followed by former smoker (10%) and non-smoker (8.2%). The odds ratio for PVR in active smokers was 1.25 (95% Cl 1.12-1.41, p<0.001), and the odds ratio for PVR in former smokers was 1.24 (95%Cl 1.15- 1.35, p<0.001).

Conclusions : To our knowledge, this is the first study to assess smoking as a risk factor for PVR in a large patient population. The findings of this study suggest that current or previous smoking is a risk factor for PVR in patients with RRD. There was not a significant difference in PVR rates in active smoker and former smoker groups.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×